Tech Center 1600 • Art Units: 1653
This examiner grants 31% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17667189 | ENHANCEMENT OF SKELETAL MUSCLE STEM CELL ENGRAFTMENT BY DUAL DELIVERY OF VEGF AND IGF-1 | Final Rejection | President and Fellows of Harvard College |
| 18227801 | Methods for Antimicrobial Susceptibility Testing | Final Rejection | The Regents of the University of California |
| 17280486 | ASSAYS FOR CELL-BASED THERAPIES OR TREATMENTS | Non-Final OA | The Regents of the University of California |
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | Non-Final OA | Genentech, Inc. |
| 16362824 | APPARATUS AND METHOD FOR BATCH PHOTOACTIVATION OF MONONUCLEAR CELLS WITH CRYOPRESERVATION | Final Rejection | Fenwal, Inc. |
| 17439251 | ISOLATION, ENRICHMENT AND EXPANSION OF CONE PROGENITOR CELLS AND USES THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 17906727 | Upregulation of Cathelicidin Gene Expression as an Adjuvant to Other Treatments for Diseases | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17842762 | FGF-18 IN GRAFT TRANSPLANTATION AND TISSUE ENGINEERING PROCEDURES | Non-Final OA | MERCK PATENT GMBH |
| 17602458 | CELL CULTURE MEDIA COMPRISING KETO ACIDS | Final Rejection | MERCK PATENT GMBH |
| 16301167 | AIRWAY MUCUS IMPACTION | Final Rejection | Washington University |
| 17607695 | COMPOSITION AND METHOD FOR CRYOPRESERVATION OF CELLS | Final Rejection | Regents of the University of Minnesota |
| 18441770 | ENZYMATIC COMPOSITIONS FOR CARBOHYDRATE ANTIGEN CLEAVAGE ON DONOR ORGANS, METHODS AND USES ASSOCIATED THEREWITH | Final Rejection | UNIVERSITY HEALTH NETWORK |
| 17879015 | Method of Recovering Nitrogen and Sulfur Resources Through Anaerobic Fermentation | Non-Final OA | SK Innovation Co., Ltd. |
| 17686236 | INCREASED HOMOGENEITY OF MYCOLOGICAL BIOPOLYMER GROWN INTO VOID SPACE | Final Rejection | Ecovative LLC |
| 16519384 | Method of Producing a Mycological Product and Product Made Thereby | Non-Final OA | Ecovative LLC |
| 17275659 | UREMIC VASCULOPATHY MODEL USING ENDOTHELIAL CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS AND UREMIC COMPLEX, AND USE THEREOF | Non-Final OA | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION |
| 17541558 | FASTING MIMICKING KETOGENIC DIET (FMD) TO PROMOTE SKELETAL MUSCLE REGENERATION AND STRENGTH | Non-Final OA | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 17714224 | Lithographic masking for spatially localized biochemical stimulus delivery | Final Rejection | The Government of the United States of America, as represented by the Secretary of the Navy |
| 16070209 | PROTEIN CAGE-STABILIZED PICKERING EMULSIONS AND THE USE THEREOF | Final Rejection | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH |
| 18800750 | SYSTEMS AND METHODS FOR GROWING CELLS IN VITRO | Final Rejection | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 17763723 | CONCENTRATED PERFUSION MEDIUM | Final Rejection | Boehringer Ingelheim International GmbH |
| 17755834 | FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE | Final Rejection | FIGENE, LLC |
| 18628538 | ENZYMATIC COMPOSITIONS FOR CARBOHYDRATE ANTIGEN CLEAVAGE, METHODS, USES, APPARATUSES AND SYSTEMS ASSOCIATED THEREWITH | Final Rejection | The University of British Columbia |
| 18258403 | BLOOD SAMPLER CONTAINING ANTI-PLATELET AGENT AND WATER-SOLUBLE MATRIX MATERIAL | Final Rejection | Radiometer Medical ApS |
| 18605672 | SYSTEMS AND METHODS FOR EX VIVO ORGAN CARE | Final Rejection | TransMedics, Inc. |
| 18277278 | CELL SHEET SUPPORT, CELL SHEET LAMINATE AND METHOD FOR PRODUCING SAME | Non-Final OA | FUKUOKA UNIVERSITY |
| 16068650 | SYSTEMS AND METHODS FOR PREPARATION OF PLATELETS | Final Rejection | Cerus Corporation |
| 18391878 | METHOD FOR IMPROVING PRODUCT TITER IN A CELL AND A CELL MEDIA FOR IMPROVING THE SAME | Final Rejection | VALITACELL LIMITED |
| 16358926 | METHOD FOR IMPROVING PRODUCT TITER IN A CELL AND A CELL MEDIA FOR IMPROVING THE SAME | Non-Final OA | VALITACELL LIMITED |
| 17435911 | METHOD FOR DETERMINING EFFICACY | Final Rejection | LDN Pharma Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy